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Abstract
Introduction. Sleep-disordered breathing (SDB) affects approximately 2–12% of the general population and the preva-
lence among patients with heart failure due to left ventricular dysfunction (LV–HF) is even higher. SDB is an important 
determinant of worse clinical outcomes in such patients. In contrast, the prevalence of SDB in pulmonary arterial 
hypertension (PAH) and its implications remain unclear. The purpose of this study was to compare relations between 
estimated apnea-hypopnoea index (eAHI) and clinical parameters in patients with LV–HF and PAH, with particular at-
tention to the consequences of SDB.
Material and methods. Eighty-one patients were screened for SDB using commercial Holter electrographic monitoring 
software that allowed evaluation of eAHI. The study population consisted of 39 LV–HF patients and 42 PAH patients.
Results. While similar N-terminal pro B-type natriuretic peptide (NT-proBNP) levels were noted in both groups, LV–HF 
patients were characterized by higher age (63 vs. 50 years, respectively, p < 0.001), higher proportion of males (87% 
vs. 40%, p < 0.0001), and higher eAHI (24 vs. 14, p < 0.001) and body mass index (BMI) (28 vs. 25 kg/m2, p < 0.001) 
values compared to the PAH group. The prevalence of SDB, defined as eAHI > 15, was 64% in the LV–HF group and 36% 
in the PAH group. Parameters of time domain heart rate variability (HRV) analysis were lower in PAH vs. LV–HF. Patients 
with LV–HF had more ventricular arrhythmias than patients with PAH. In the LV–HF group, eAHI correlated positively with 
NT-proBNP level, and negatively with left ventricular ejection fraction and the mean heart rate. The median eAHI was 
18.7, and patients with eAHI above the median had more supraventricular arrhythmias. In the PAH group, a negative 
correlation between eAHI and age was found. In the subgroup with eAHI < 15, rMSSD values were higher and idiopathic 
PAH predominated. The median eAHI was 8.4, and patients with eAHI above the median were younger and had higher 
BMI values.
Conclusions. Sleep-disordered breathing was more frequent and eAHI was higher in patients with LV–HF compared to 
those with PAH, although it was present in more than one third of patients in the latter group. Higher eAHI values indica-
ted more severe hemodynamic dysfunction in patients with LV–HF. In the PAH group, higher eAHI was associated with 
clinical presentation at a younger age. Patients with PAH seem to have worse HRV parameters compared to patients 
with left ventricular dysfunction.
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Introduction
Sleep-disordered breathing (SDB) is a severe, potentially 
life-threatening clinical syndrome characterized by occur-
rence of sleep apnea episodes leading to sympathetic 
system activation, which results in multiple awakenings and 
sleep defragmentation. The estimated prevalence of sleep 
apnea in the general population, depending on the source, 
ranges from 2% in women and 4% in men [1] to 5.7% in 
women and 12.4% in men [2]. According to the current 
guidelines, the major diagnostic test to investigate SDB, 
which allows the definite diagnosis, is polysomnography 
(PSG). As this method is not widely available, screening 
methods are currently used, based on, among others, 
sleep polygraphic techniques which are widely available 
and may be used on an outpatient basis. One of the quan-
titative parameters used to evaluate the severity of SDB 
is the apnea/hypopnea index (AHI) [3, 4], defined as the 
number of apnea and hypopnea episodes per an hour of 
sleep. AHI values > 15 or > 5 with concomitant clinical 
symptoms of sleep apnea syndrome are considered abnor-
mal and indicate significant sleep apnea. Clinical studies 
[5, 6] confirmed an association between sleep apnea and 
hypertension, myocardial infarction incidence, strokes, and 
development of heart failure.
Due to limited data, the association between sleep 
apnea and pulmonary hypertension and its significance are 
still unclear. A role of several parameters in the evaluation 
of disease severity, stability of its course, and prognosis 
has been recently documented [7]. However, studies on the 
usefulness of new parameters are still underway. Of note, 
pulmonary arterial hypertension (PAH) is a severe disease 
characterized by constantly elevated pulmonary vascular 
resistance, ultimately leading to right ventricular failure 
and death [8]. Major causes of mortality are progressing 
right ventricular failure, sudden cardiac death (including 
arrhythmic death), and respiratory failure [9]. Disease 
progression is observed despite availability of drugs used 
specifically for its treatment [10].
As already mentioned, the prevalence of SDB in the 
population of patients with PAH and right ventricular fai-
lure and clinical implications of this phenomenon remain 
poorly understood. It seems that the prevalence of sleep 
apnea among patients with confirmed PAH may be higher 
compared to the general population. In the study by Du-
mitrascu et al., AHI values > 10 were found in more than 
25% of patients with established PAH in the World Health 
Organization (WHO) functional class II or III [11]. For a com-
parison, SDB is present in a large proportion (40–70%) of 
patients with heart failure due to left ventricular systolic 
dysfunction (left ventricular heart failure, LV–HF) [12] 
and is known to be an important factor determining worse 
outcomes in these patients [13–15].
Taking into account all the above issues, we designed 
a study to determine the prevalence of SDB in patients 
with PAH of various aetiology and patients with LV–HF 
with secondary pulmonary hypertension, with particular 
attention to the consequences of SDB.
Material and methods
The study included 81 patients hospitalized in a single 
centre experienced in hospital treatment and further 
outpatient care for adult patients with PAH. The patients 
were included in the study regardless of the presence or 
absence of sleep apnea syndrome symptoms (e.g., snoring, 
excessive daytime sleepiness, witnessed apnea episodes). 
All patients gave their written informed consent for study 
participation. The study was performed in accordance with 
the Helsinki Declaration. The study protocol was approved 
by a local bioethics committee (RNN/194/15/KE). The 
study population was divided into two groups:
 — 42 patients with confirmed PAH (the mean pulmonary 
artery pressure [MPAP] > 25 mm Hg during right heart 
catheterization). They received specific therapy accord-
ing to the pulmonary hypertension therapy program. 
According to the European Society of Cardiology (ESC) 
clinical classification of pulmonary hypertension, the 
included patients were in the group 1 (including 19 pa-
tients with idiopathic PAH, 7 patients with PAH due to 
congenital heart disease and 6 patients with connective 
tissue disease);
 — 39 patients with documented systolic heart failure due 
to coronary artery disease. The inclusion criteria were: 
left ventricular ejection fraction (LVEF) ≤ 50%, systolic 
pulmonary artery pressure (SPAP) > 30 mm Hg, New 
York Heart Association (NYHA) functional class II–III, 
and optimal drug therapy.
The exclusion criteria were as follows: moderate or 
severe left heart valvular dysfunction, atrial fibrillation/ 
/flutter, NYHA class IV, acute myocardial infarction, a pre-
vious diagnosis of sleep apnea by PSG, and lack of patient 
consent for participation in the study.
In all patients, in addition to history taking and physical 
examination including anthropometric parameters, 24- 
-hour Holter electrocardiographic (ECG) monitoring using 
commercially available software to estimate AHI, standard 
transthoracic echocardiography, and laboratory tests were 
performed.
Twenty-four hour ECG monitoring was performed using 
a 3-channel digital recorder (Del Mar Reynolds Medical 
Lifecard CF) and analysed using the Pathfinder 700 and 
Lifescreen Apnea (Spacelabs Healthcare, Issaquah WA, 
USA) software. As mentioned above, sleep apnea activates 
autonomic nervous system which results in a specific mo-
dulation of sinus rhythm. The Lifescreen Apnea software 
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calculates the likelihood of apnea/hypopnea events based 
on changes of R-R intervals in the ECG and the respiratory 
signal obtained from the ECG analysis. The methods were 
described in detail in the study by De Chazal et al. [16]. 
The likelihood of apnea/hypopnea events is calculated for 
subsequent 1-minute periods and then for longer periods. 
If the likelihood is > 50%, the algorithm considers the 
event to occur and the overall result is reported as the 
estimated AHI (eAHI) for the whole sleep period. Estimated 
AHI values ≤ 5 are normal, eAHI > 15 indicates significant 
SDB, and intermediate values are considered borderline. 
The minimum required sleep length was 6 hours. The time 
of falling asleep and awakening was noted by the patient 
in a diary received for the period of Holter monitoring. In 
addition to eAHI calculation, a typical analysis of cardiac 
rhythm was performed, with evaluation of the mean, max-
imum, and minimum heart rate (mean HR, max HR, min 
HR), the number of ventricular extrasystoles (ExV) and 
supraventricular extrasystoles (ExSV), and the occurrence 
of arrhythmic events including non-sustained ventricular 
tachycardia (nsVT) and supraventricular tachycardia (SVT). 
Heart rate variability (HRV) analysis was also performed 
according to the guidelines [17], with calculation of three 
parameters: the standard deviation of all sinus rhythm 
R-R intervals (SDNN), the square root of the mean of the 
squares of the successive differences between adjacent 
R-R intervals (rMSSD), and the triangular index, calculated 
as the total number of R-R intervals divided by the number 
of R-R intervals with the most frequently seen duration.
Transthoracic echocardiography was performed using the 
Vivid E9 system with the M5S-D 2D 1.5–4.5 MHz probe. Stand-
ard measurements were performed in typical two-dimensional 
echocardiographic views. Tricuspid annular plane systolic 
excursion (TAPSE) in M-mode was measured to evaluate right 
ventricular function, and TAPSE values < 16 mm were consid-
ered significantly reduced [18]. Calculation of SPAP was based 
on the measurement of peak tricuspid regurgitation pressure 
gradient and the estimated mean right atrial pressure. The 
modified Simpson method was used to calculate LVEF.
Statistical analysis
Normal distribution of the variables was evaluated using 
the Shapiro-Wilk test. Two-group comparisons were per-
formed using the Student t test for independent variables 
for normally distributed variables and the Mann-Whitney 
U test for non-normally distributed variables. Correlations 
were evaluated using the nonparametric Spearman’s rank 
correlation coefficient. p < 0.05 was considered significant. 
Calculations were performed using the STATISTICA v10.0 
statistical package and the Microsoft Excel spreadsheet.
Results
Population characteristics  
and group comparison
Baseline patient characteristics and comparison of the 
two study groups are shown in Tables 1 and 2. We found 
significant differences in regard to age and the body mass 
index (BMI), with lower values in the PAH group. The two 
groups also differed by gender distribution, with a higher 
proportion of women in the PAH group. Elevated N-terminal 
pro-B-type natriuretic peptide (NT-proBNP) levels were 
found in both group but did not differ significantly. The 
results of 24-hour Holter ECG monitoring and echocardio-
graphic studies are shown in Table 2.
Patients with PAH were characterized by good left 
ventricular systolic function and very high SPAP values 
compared to the LV–HF group. Patients with LV–HF were 
characterized by higher rates of ventricular arrhythmia (ExV 
and nsVT), while PAH patients had more SVT. We found 
significantly lower HRV parameters in the PAH group. The 
prevalence of SDB is shown in Figures 1 and 2.
Table 1. Group characteristics and comparison
Parameter Patients with left ventricular systolic 
dysfunction (n = 39)
Patients with pulmonary arterial  
hypertension (n = 42)
P value
Age [years], mean ± SD 63 ± 9 50 ± 17 < 0.001
Male gender [n (%)] 34 (87%) 17 (40%) < 0.0001
BMI [kg/m2], mean ± SD 28 ± 4 25 ± 5 < 0.001
NYHA/WHO functional class:
• II [n (%)] 17 (44%) 21 (50%) NS
• III [n (%)] 22 (56%) 21 (50%) NS
NT-proBNP [pg/mL], mean ± SD 1855 ± 2516 1521 ± 1929 NS
Etiology: n (%) Coronary artery disease: 39 (100%) Idiopathic: 19 (45%)
CHD: 17 (40%) –
CTD: 6 (15%)
SD — standard deviation; BMI — body mass index; NYHA — New York Heart Association; WHO — World Health Organization; NS — nonsignificant; NT-proBNP — N-terminal pro-B-type natriuretic peptide;  
CHD — congenital heart disease; CTD — connective tissue disease
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Clinical importance of sleep-disordered  
breathing as evaluated based on eAHI values
In patients with LV–HF, we found a significant positive cor-
relation between eAHI and NT-proBNP levels (Spearman 
R = 0.45, p = 0.005) and a negative correlation between 
eAHI and LVEF (Spearman R = –0.39, p = 0.01). Thus, 
patients with LV–HF and more severe sleep apnea (eAHI 
> 15) had significantly lower LVEF (p = 0.002) and higher 
NT-proBNP levels (p = 0.01). In Holter ECG monitoring, 
eAHI was inversely related to the mean HR (Spearman 
R = –0.38, p = 0.02). In addition, a trend for more ExSV 
with higher eAHI values was noted in the LV–HF group, 
which achieved statistical significance for eAHI above the 
median (18.7, p = 0.03).
In the PAH group, eAHI values were inversely related to 
age (Spearman R = –0.38, p = 0.01). Patients with eAHI 
> 15 had significantly lower rMSSD values (p = 0.03) and 
showed a trend for lower SDNN values (p = 0.07). Abnormal 
Table 2. Electrocardiographic and echocardiographic group characteristics (data shown are mean values ± standard deviation [SD]  
unless indicated otherwise)
Parameter Patients with left ventricular  
systolic dysfunction (n = 39)
Patients with pulmonary  
arterial hypertension (n = 42)
P value
Mean HR [1/min] 69 ± 9 70 ± 8 NS
Maximum HR [1/min] 104 ± 14 121 ± 91 NS
Minimum HR [1/min] 53 ± 7 57 ± 15 0.01
ExV [n] 2144 ± 5572 292 ± 559 < 0.0001
nsVT episodes [n] 0.9 ± 1.7 0.2 ± 0.6 0.01
Occurrence of nsVT [%] 20 9
ExSV [n] 210 ± 625 294 ± 1369 NS
SVT episodes [n] 1.7 ± 4.8 3.3 ± 10 < 0.05
eAHI [1/hour of sleep] 24 ± 14 14 ± 15 < 0.001
SDNN [ms] 118 ± 41 100 ± 37 0.03
rMSSD [ms] 31 ±22 22 ± 11 0.03
TI 33 ± 12 26 ± 10 0.01
LVEF [%] 33 ± 8 56 ± 3 < 0.000001
SPAP [mm Hg] 40 ± 10 93 ± 27 < 0.000001
TAPSE [mm] 19.8 ± 5 18.8 ± 4 NS
HR — heart rate; NS — nonsignificant; ExV — ventricular extrasystole; nsVT — nonsustained ventricular tachycardia; ExSV — supraventricular extrasystole; SVT — supraventricular tachycardia; eAHI — estima-
ted apnea–hypopnea index; SDNN — standard deviation of all sinus rhythm R-R intervals; rMSSD — square root of the mean of the squares of the successive differences between adjacent R-R intervals; 
IT — triangular index (total number of R-R intervals divided by the number of R-R intervals with the most frequently seen duration); LVEF — left ventricular ejection fraction; SPAP — systolic pulmonary artery 
pressure; TAPSE — tricuspid annular plane systolic excursion
Figure 1. Prevalence of sleep-disordered breathing in patients 
with left ventricular systolic dysfunction and secondary pulmonary 
hypertension; eAHI — estimated apnea–hypopnea index
Figure 2. Prevalence of sleep-disordered breathing in patients 
with pulmonary arterial hypertension; eAHI — estimated apnea– 
–hypopnea index
65.71%
TR–
eAHI < 15
64%
eAHI > 15
36%
Patients with pulmonary arterial hypertension
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and higher eAHI values were more frequent in patients with 
PAH aetiology other than idiopathic pulmonary hypertension 
(p = 0.03). PAH patients with eAHI values above the median 
(i.e., > 8.4) were characterized by lower age (p = 0.008) 
and higher BMI values (p = 0.04).
Discussion
Our study dealt with a rare disease which PAH is, but we 
were able to include 42 patients with confirmed PAH, the 
number similar or higher than in other publications. We 
reported findings for a wide profile of clinical parameters, 
including the occurrence of SDB. It is a novel approach to 
the problem of PAH, particularly in the context of active-
ly searching sleep apnea among patients with PAH, as 
only few studies on this issue were reported previously. 
A strength of our study is a focus on the importance of 
eAHI in relation to the parameters conventionally evaluated 
during the clinical management.
Of note, patients included in the study had a similar 
functional status (NYHA/WHO classification, similar mean 
NT-proBNP levels) but significant differences were found 
between the two groups. Regarding arrhythmic events, 
ventricular arrhythmia clearly predominated in the LV–HF 
group, while supraventricular arrhythmia was more severe 
in patients with PAH. While malignant ventricular arrhythmia 
is a major cause of sudden cardiac death in heart failure 
(resulting in prophylactic implantation of cardioverter-defi-
brillators), it seems that sudden cardiac deaths in the PAH 
population (amounting to about 28% of all deaths) are rather 
caused by non-arrhythmic mechanisms [19]. On the other 
hand, SVT is believed to have a major effect on cardiac 
function, leading to worse outcomes in patients with PAH. 
Although patients with atrial flutter/fibrillation were exclud-
ed from our study, short SVT episodes were clearly more 
prevalent in the PAH group compared to the LV–HF group.
We confirmed a very high prevalence of SDB in patients 
with left ventricular systolic dysfunction. In these patients, 
higher eAHI values indicated a much worse hemodynamic 
function (lower LVEF and higher NT-proBNP values) and 
a higher rate of supraventricular arrhythmia. Relations 
between natriuretic peptide levels, LVEF and SDB in heart 
failure were documented in the literature [20, 21]. Our 
findings are also consistent with previous reports of SDB 
promoting supraventricular arrhythmia, including both 
premature supraventricular beats and atrial fibrillation 
[22]. A high rate of SDB seen in patients with established 
Group 1 pulmonary hypertension (36%) is a novel obser-
vation which may contribute to better understanding of 
this pathology. Recently, Minic et al. [23] used PSG and 
showed that the rate of SDB in PAH may be even higher. 
They also found that the rate and severity of SDB increased 
with patient age, similarly to the trend observed in the 
general population. An unexpected finding of our study is 
the observation of an association between younger age 
and SDB in PAH patients. Perhaps it is an effect of a high 
proportion (40%) of younger patients with congenital heart 
disease in our study group. The association between age 
and SDB is thus not so clearly defined in patients with 
PAH and may depend on the group characteristics. In fact, 
SDB were more related to congenital heart disease and 
connective tissue disease than to idiopathic PAH. Higher 
BMI values are an important factor increasing the severity 
of sleep apnea in PAH, similarly to other observations and 
studies in the general population [24].
Multiple studies showed that low HRV parameters are 
significantly associated with worse outcomes, particularly 
in patients with previous myocardial infarction or congestive 
heart failure. Autonomic nervous system function distur-
bances have been recently reported by Polish authors 
[25]. Of note, the latter study included only 25 patients 
with group 1 pulmonary hypertension who were compared 
to healthy subjects. In our study, HRV parameters were 
found to be much worse even compar ted to patients with 
heart failure, which is an even more worrisome finding. 
In addition, HRV parameters were even worse in patients 
with high eAHI values. Whether this may have an effect on 
long-term outcomes, for exam ple by promoting malignant 
arrhythmia and sudden cardiac deaths, is clearly an issue 
which deserves further studies. It is known that increased 
sympathetic nervous system activity and impaired HRV 
are among major risk factors for arrhythmia in PAH [19].
Study limitations
The study was performed in a single centre due to rare 
occurrence of PAH, and the number of patients was 
limited. The group with left ventricular dysfunction in-
cluded consecutive patients hospitalized in the centre, 
considering the inclusion and exclusion criteria. Sleep 
apnea was evaluated using a screening method. How-
ever, this method was previously verified against PSG 
[26], and its good reproducibility in subsequent days 
was documented [27].
Conclusions
The prevalence of SDB in patients with confirmed pul-
monary hypertension is very high, perhaps in as many 
as more than one third of patients. Several factors have 
been identified that indicate a higher likelihood of SDB in 
patients with pulmonary hypertension, including younger 
age, higher BMI, and PAH due to congenital heart disease 
and connective tissue disease. Sleep apnea contributes to 
an adverse modulation of the autonomic nervous system 
activity in patients with PAH. Our findings should prompt 
further studies to confirm an association between SDB and 
PAH, and document the effect of SDB on the prognosis and 
treatment outcomes in these patients.
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Streszczenie
Wstęp. Zaburzenia oddychania w czasie snu (SDB) dotyczą 2–12% ogólnej populacji; jeszcze wyższy odsetek obserwuje 
się wśród pacjentów z niewydolnością serca spowodowaną dysfunkcją lewej komory (LV–HF). Występowanie SDB w tęt-
niczym nadciśnieniem płucnym (PAH) oraz jego implikacje kliniczne pozostają niejasne. Celem pracy było porównanie 
relacji między oszacowanym wskaźnikiem bezdechu sennego (eAHI) a parametrami klinicznymi pacjentów z LV–HF 
i PAH, z uwzględnieniem konsekwencji obecności bezdechu sennego.
Materiał i metody. Do badania włączono 81 chorych, u których wykonano 24-godzinne monitorowanie elektrokardio-
graficzne metodą Holtera w celu obliczenia eAHI. Populację podzielono na dwie grupy — 39 chorych z LV–HF o etiologii 
wieńcowej oraz 42 chorych z PAH.
Wyniki. W grupie LV–HF dominowali mężczyźni (87% v. 40% w grupie PAH; p < 0,0001), w starszym wieku (63 v. 50 lat 
w grupie PAH; p < 0,001), z wyższymi wartościami wskaźnika masy ciała (BMI) (28 v. 25 kg/m2; p < 0,001) oraz niższą 
frakcją wyrzutową lewej komory (LVEF) (33 v. 56%; p < 0,000001), choć grupy charakteryzowała podobna średnia 
wartość stężenia N-końcowego fragmenty propetydu natriuretycznego typu B (NT-proBNP). Zaburzenia oddychania 
w czasie snu, zdefiniowane jako eAHI ponad 15, stwierdzono u 64% chorych z LV–HF i u 36% pacjentów z PAH. Wyższe 
wartości eAHI występowały w grupie LV–HF (24 v. 14; p < 0,001). Pacjenci z LV–HF cechowali się obecnością licznych 
arytmii komorowych, a przy wartościach eAHI powyżej mediany (> 18,7) potwierdzono zwiększoną częstość występowa-
nia arytmii nadkomorowej. W PAH obserwowano istotnie obniżone parametry czasowej zmienności rytmu zatokowego 
(HRV). W grupie LV–HF wykazano korelację eAHI z wartościami NT-proBNP i odwrotną korelację z LVEF oraz średnią 
dobową częstotliwością pracy serca. Z kolei eAHI w grupie chorych z PAH nie korelowało z NT-proBNP ani LVEF, ale było 
odwrotnie proporcjonalne do wieku. Wśród chorych z PAH i wartościami eAHI poniżej 15 przeważali pacjenci z PAH 
o etiologii idiopatycznej, z wyższymi wartościami rMSSD. Pacjentów z PAH i wartościami eAHI powyżej mediany (> 8,4) 
charakteryzowały młodszy wiek oraz wyższe wartości BMI.
Wnioski. Zaburzenia oddychania podczas snu u pacjentów z PAH nie były tak częste jak u chorych z LV–HF, ale dotyczyły 
więcej niż 1/3 populacji. Wyższe wartości eAHI u chorych z LV–HF wskazują na zaawansowaną dysfunkcję hemodyna-
miczną. U pacjentów z PAH obecność SDB wiąże się z zachorowaniem w młodszym wieku i wskazuje na istotną dysre-
gulację w zakresie autonomicznej kontroli pracy serca.
Słowa kluczowe: zaburzenia oddychania podczas snu, bezdech senny, tętnicze nadciśnienie płucne, niewydolność 
serca
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